Market Trial Coordinators' Meeting - I-SEM Project Update

1. Market Trial Co-ordinators’ Meeting I-SEM Project Dublin, 24 April 2018

2. Agenda The Agenda for the session is as follows: • Overall Status • Analysis • 168 Hour Metric • Application Status • AOB

3. Timelines and Milestones Cutover Plan

4. Proposed Timeline

5. Impact on Market Trial Change Request Currently in progress Market Trial Continues in Scenario 7 (Unscripted) Stable systems from 1st June 168 Hour Trial metric monitored daily Working with Vendors regarding MT extension Continue with daily calls / weekly reports Continue to issue daily run sheets Trial will end 31st August Planning for 4 weeks cutover Revised Transition / cutover plan will be released

6. Agenda The Agenda for the session is as follows: • Overall Status • Analysis • 168 Hour Metric • Application Status • AOB

7. Analysis - Imbalance Pricing • Issues • FPN=0 where no FPNs • DI history • RT Availability Defect • Timestamp Defect • Memory Allocation • QBOA defects • Otherwise, price calculation performing as intended. • Issues to be addressed in next release • DI history (in test) • QBOA defects (in test) • Refinement of flagging (in test – no impact on price) • Data storage (in test)

8. PIMB vs QBOA (20th – 23rd April) 20th 21st 22nd 23rd

9. Analysis – Queries submitted by scenario

10. Analysis – Queries response times

11. Ex-Ante Market Analysis DAM – average clearing price and volumes

12. Ex-Ante Market Analysis Volumes from ex-ante auctions. Highest volumes clearing in DAM

13. Ex-Ante Market Analysis Prices in DAM generally still following the load cleared

14. Ex-Ante Market Analysis Linkage still there in IDA1, though not as clear

15. Ex-Ante Market Analysis IDA2 price vs volume shows opposite trend – prices raise as volume drops. IDA2 so far appears very thin market.

16. Ex-Ante Market Analysis IDA3 price vs volume.

17. Ex-Ante Market Analysis Traded volumes (aggregate across markets)

18. Ex-Ante Market Analysis Lowest volumes relate to day on which DAM first cancelled

19. Ex-Ante Market Analysis DAM prices generally in a range between €30 and €70

20. Ex-Ante Market Analysis Intraday auction prices appear more volatile with higher prices common in later hours;

21. Ex-Ante Market Analysis Low volume of purchase orders submitted ;

22. Ex-Ante Market Analysis More than enough generators submitted “Price Taker Bids” to cover full demand

23. Ex-Ante Market Analysis No interconnector or assetless trading also likely to have contributed to the outcomes

24. Ex-Ante Market Analysis Cross border volumes clearly allocated according to price variance in DAM;

25. Ex-Ante Market Analysis Just to look at another example across all ex-ante auctions;

26. Ex-Ante Market Analysis IDA1 shows larger fluctuations later in the day as prices are more volatile;

27. Ex-Ante Market Analysis Shorter trading periods in intraday auctions give rise to faster price changes, with ramp rates potentially limiting cross border flows capability to respond;

28. Ex-Ante Market Analysis Flows in the “wrong” direction should not be unexpected but they are outliers rather than the norm;

29. Ex-Ante Market Analysis • All the data used here is being made available on the project website on a weekly basis; • SEMOpx Auction Results spreadsheet includes one week of auction summary data including cross border flows and BETTA prices; • Bid File also being provided for each auction; • This is the same data as published in French csv format on the SEMOpx site but is reformatted with some additional data analysis provided;

30. Settlement Reallocation Agreements • Have received queries about when we plan to include SRAs in market trial; • There have been some miscommunciations on this issue; • The Market Trial Team had always intended that SRAs could be applied as part of scenario 7; • Participants expected that we would apply the SRAs already submitted to the transitional team during the registration process; • Market Trial Team expected Participants to submit SRAs directly to the trial email (were not actually aware of other submissions);

31. Settlement Reallocation Agreements • Now that we’re aware of these submissions, we are liaising with the transition team; • They have requested that we limit SRAs applied in the Market Trial to those who have submitted the relevant paper work; • That is, if a Participant advised of intended SRAs as part of their B17 but have not submitted formal paper work, this should not be applied; • We propose to apply all SRAs formally submitted from next week; • This should see them being applied in credit risk calculations and billing jobs from week commencing May 7th; • Market Trial team is open to comment if Participants have other views;

32. Agenda The Agenda for the session is as follows: • Overall Status • Analysis • 168 Hour Metric • Application Status • AOB

33. 168 Hour Metric • Consecutive days of successful operations • Provide all participants with minimum 7 days notice of weekend operations • A subsequent failure against the scorecard will reset the clock

34. 168 Hour Metric The 168-Hour Operations Trial establishes the conduct of operations by market participants to verify I-SEM business processes, systems functionality, integration, and stability • Monitored Daily against scorecard • Focus on main market capabilities of • Ex-Ante • Balancing Market • Settlements • Reporting

35. Agenda The Agenda for the session is as follows: • Overall Status • Analysis • 168 Hour Metric • Application Status • AOB

36. (a) System Defects I-SEM: Market Trial Priority Defects for Go-Live - Detailed Report Last Updated: 23 Apr 2018

37. What’s Included?

38. Release Schedule of Priority Defects for Go-Live: Summary as at 12-Mar-18

39. Release Schedule of Priority Defects for Go-Live: Summary as at 23-Mar-18

40. Release Schedule of Priority Defects for Go-Live: Summary as at 30-Mar-18

41. Release Schedule of Priority Defects for Go-Live: Summary as at 09-Apr-18

42. Release Schedule of Priority Defects for Go-Live: Summary as at 11-Apr-18

43. Release Schedule of Priority Defects for Go-Live: Summary as at 16-Apr-18

44. Release Schedule of Priority Defects for Go-Live: Summary as at 23-Apr-18

45. Schedule of Priority Defects for Go-Live:Defect Progression

46. Baseline Comparison “Planned 03-Apr” 12-Mar-18 / 23-Apr-18

47. Baseline Comparison “Planned 22-Apr” 12-Mar-18 / 23-Apr-18

48. 03 (11) April 2018 In EG Testing + Test Closed + 22 (30) April 2018 Release Pending Release Schedule of Priority Defects for Go-Live: Apr 11 MMS Defect Release Schedule / Analysis of Defect Impact Focus: Resolve high impact defects to facilitate 168-hour testing in Scenario 7 of Market Trial By The Numbers: Severity (1,2,3): 0, 0, 1 Audience (MP, Int): 0, 1 Functional Areas Addressed and the Impact to Market Participants:

49. 03 (11) April 2018 In EG Testing + Test Closed + 22 (30) April 2018 Release Pending Release Schedule of Priority Defects for Go-Live: In EG Testing + Test Closed + Apr 30 + Release Pending MMS Defect Release Schedule / Analysis of Defect Impact Focus: Resolve remaining priority defects to facilitate I-SEM go-live and continued trialling for MPs in Market Trial By The Numbers: Severity (1,2,3): 0, 23, 31 Audience (MP, Int): 18, 36 Functional Areas Addressedandthe Impact to Market Participants:

50. In EG Testing + Test Closed + 03 (11) April 2018 In EG Testing + Test Closed + 22 (30) April 2018 Release Pending Release Schedule of Priority Defects for Go-Live: In EG Testing + Test Closed + Apr 30 + Release Pending MMS Defect Release Schedule / Analysis of Defect Impact Functional Areas Addressed and the Impact to Market Participants: